Amelotex, rectal 15 mg 6 pcs

NSAID, has anti-inflammatory, antipyretic, analgesic effects. It belongs to the class of oxycams; a derivative of enolic acid.

The mechanism of action is inhibition of Pg synthesis as the result of selective suppression of COX2 enzymatic activity.

When administered in high doses, prolonged use and individual characteristics of the body COX2 selectivity decreases.

Suppresses Pg synthesis in the area of inflammation to a greater extent than in the gastric mucosa or kidneys, which is associated with relatively selective inhibition of COX2. Less often causes gastrointestinal erosive and ulcerative diseases.

Indications

Inflammatory and degenerative joint diseases (arthrosis, osteoarthritis), rheumatoid arthritis, ankylosing spondylitis (ankylosing spondylitis).

Pharmacological effect

NSAIDs have anti-inflammatory, antipyretic and analgesic effects. Belongs to the class of oxicams; enolic acid derivative.

The mechanism of action is inhibition of Pg synthesis as a result of selective suppression of the enzymatic activity of COX2.

When prescribed in high doses, long-term use and individual characteristics of the organism, COX2 selectivity decreases.

Suppresses Pg synthesis in the area of ​​inflammation to a greater extent than in the gastric mucosa or kidneys, which is associated with relatively selective inhibition of COX2. Less commonly causes erosive and ulcerative diseases of the gastrointestinal tract.

Special instructions

If peptic ulcers or gastrointestinal bleeding occur, or side effects on the skin and mucous membranes develop, the drug should be discontinued.

In patients with reduced BCC and reduced glomerular filtration (dehydration, CHF, liver cirrhosis, nephrotic syndrome, clinically significant kidney disease, taking diuretics, dehydration after major surgery), clinically significant chronic renal failure may occur, which is completely reversible after discontinuation of the drug (in such patients, daily diuresis and renal function should be monitored at the beginning of treatment). If there is a persistent and significant increase in transaminases and changes in other indicators of liver function, the drug should be discontinued and control tests performed.

In patients with an increased risk of side effects, treatment begins with a dose of 7.5 mg. In the terminal stage of chronic renal failure in patients on dialysis, the dose should not exceed 7.5 mg/day.

During the treatment period, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions (if dizziness and drowsiness occur).

To reduce the risk of developing adverse events from the gastrointestinal tract, the minimum effective dose should be used for the shortest possible short course.

Active ingredient

Meloxicam

Composition

Rectal suppositories are greenish-yellow in color, torpedo-shaped.

1 sup.meloxicam 15 mg

Excipients:

solid fat (Supposir VR) – 1628.5 mg,

macrogol glyceryl hydroxystearate – 16.5 mg.

3 pcs. – contour cell packaging (2) – cardboard packs.

Contraindications

Peptic ulcer of the stomach and duodenum in the acute phase, severe liver dysfunction, renal failure (without hemodialysis), pregnancy, childhood and adolescence up to 15 years, hypersensitivity to meloxicam and other NSAIDs (including salicylates).

Side Effects

From the digestive system: dyspepsia, nausea, vomiting, abdominal pain, constipation, intestinal colic, diarrhea, esophagitis, stomatitis; rarely – erosive and ulcerative lesions of the gastrointestinal tract.

From the side of the central nervous system: dizziness, headache, tinnitus.

From the cardiovascular system: increased blood pressure, palpitations, swelling, hot flashes.

From the urinary system: changes in laboratory parameters of renal function.

From the hematopoietic system: anemia, leukopenia, thrombocytopenia.

Allergic reactions: bronchospasm, photosensitivity, itching, rash, urticaria.

Interaction

With simultaneous use, it is possible to reduce the effectiveness of antihypertensive drugs (beta-blockers, ACE inhibitors, vasodilators).

When used simultaneously with anticoagulants, the risk of bleeding increases.

When used simultaneously with diuretics, the risk of developing renal failure in patients in a state of dehydration increases.

When used simultaneously with NSAIDs, the risk of developing gastrointestinal ulcers and gastrointestinal bleeding increases.

When used simultaneously with lithium preparations, the concentration of lithium in the blood plasma increases.

With simultaneous use, cholestyramine accelerates the elimination of meloxicam.

When used simultaneously with methotrexate, the myelosuppressive effect may be enhanced; with cyclosporine – the nephrotoxic effect of cyclosporine may be enhanced.

Overdose

Not described

Manufacturer

Pharmproject, Russia